

DORSET MEDICINES ADVISORY GROUP Recommendation Summary

Formerly the Bournemouth, Dorset and Poole Health Technologies Forum, DMAG represents the four provider Trusts and GPs within the Clinical Commissioning Group (CCG). It provides recommendations to the CCG on the prescribing and commissioning of medicines.

Summary of recommendations considered at a meeting of the group on 13th January 2015

PRODUCT	DECISION	COMMENTS
1. Products re-categorised		
Jaydess®	Green	<p>Re-categorised from “not recommended”.</p> <p>For use only in practices and organisations commissioned by Public Health to fit I.U.Ds and as a second line to Mirena®. Guidelines will be developed to ensure Jaydess® is only used for those within specific groups:</p> <ul style="list-style-type: none"> • Patient wants IUS but uterine cavity on sounding is between 5-7cm; • Patient has previously experienced ovarian cysts; • Patient has experienced hormonal side effects with alternative contraception; • Patient would like to have contraceptive cover for three years, instead of five; • Patient cannot cope psychologically with amenorrhoea.
Nalmefene	Amber with shared	Re-categorised from “not recommended”. A comprehensive pathway and shared care guideline is being developed to support the use of nalmefene in association with

PRODUCT	DECISION	COMMENTS
	care	psycho-social support in accordance with NICE TA 325. These will be published on the formulary website w/c 23 February 2015.
Lubiprostone	Green	Re-categorised from “red”. A primary care guideline for management of chronic constipation in primary care has been developed to support the use of lubiprostone in accordance with NICE TA 318. See also the local commissioning statement .
Prucalopride	Green	Re-categorised from “amber”. A primary care guideline for management of chronic constipation in primary care has been developed to support the use of prucalopride in accordance with NICE TA 211. See also the local commissioning statement .
2. New requests		
Evra® patch	Green	Evra® must only be prescribed as a third line option when other routes of administration have been considered unsuitable. Refer to local guidance .
Linaclotide	Green	A primary care guideline for management of chronic constipation in primary care has been developed to support the use of linaclotide where the constipation is associated with IBS. See also the local commissioning statement .
Reflectant (Dundee) sunscreen	Amber	A commissioning statement for the use of Dundee sunscreen was approved for patients with sensitivity to visible light, most commonly due to solar urticaria and porphyrias. In most other instances patients should be encouraged to purchase an alternative titanium based product.
Pigmanorm®	Not recommended	The commissioning statement recommending that Pigmanorm® cream is NOT recommended in Dorset for the treatment melisma or hyperpigmentation was accepted. This categorisation will be considered for extension to all hydroquinone

PRODUCT	DECISION	COMMENTS
		containing creams.
Anoro Ellipta®	Not recommended	A commissioning statement not recommending the use of Anoro Ellipta for COPD was approved.
Duoresp Spiromax®	Not recommended	A commissioning statement not recommending the use of Duoresp Spiromax for asthma or COPD was approved.
Striverdi Respimat®	Not recommended	A commissioning statement not recommending the use of Striverdi Respimat for COPD was approved.
N-acetylcysteine (oral)	Not recommended	A commissioning statement not recommending the use of N-acetylcysteine for idiopathic pulmonary fibrosis was approved. Further guidance will be provided by the CCG's medicines management team for patients in primary care currently receiving the drug for this indication.
Freestyle libre blood glucose monitoring system	Not recommended	A commissioning statement not recommending the use of the Freestyle libre blood glucose monitoring system was approved.
3. Products considered by NICE		
Erythropoiesis stimulating agents for anaemia in patients with cancer on chemotherapy NICE TA 323	Red	Newly commissioned as an option for treating anaemia in people with cancer who are having chemotherapy. Commissioning statement available.
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and pulmonary embolism NICE TA 327	Amber, with shared care	A commissioning statement and shared care guideline are available to support TA 327.

PRODUCT	DECISION	COMMENTS
4. Miscellaneous recommendations by DMAG		
Guideline for the management of hypomagnesaemia		The guidance and pathway includes the recommendation that where possible the licensed product, Magnaspartate should be used for the treatment and prevention of magnesium deficiency.
Guideline for glucose management in type 2 diabetes in adults		Updated guideline available.
Primary care guideline for the management of chronic constipation		A primary care guideline for management of chronic constipation in primary care has been developed to support the use of linaclotide, prucalopride and lubiprostone.
Guideline to support the use of calcitonin in acute bone loss due to sudden immobilisation		Guideline to support primary care clinicians in prescribing calcitonin in acute bone loss.
Clarification of supply and commissioning of transplant related immunosuppressant drugs		Guideline to clarify the commissioning arrangements and traffic light categorisations of immunosuppressants , particularly mycophenolate and tacrolimus in renal transplant patients (red) and other transplant patients (amber until repatriation has occurred)
British Association of Dermatologists special list		Available to download. Adopted for use locally as red products apart from Dundee sunscreen and Pigmanorm® (see above)

Classification of products:

'RED' drugs for hospital use only

'AMBER with shared care' drugs suitable for use with shared care arrangements

'AMBER' drugs suitable for use without shared care arrangements

'GREEN' drugs suitable for prescribing in primary and secondary care

'Not Recommended' – drugs not recommended for use in Dorset

The new traffic light system can be found on the Dorset CCG internet at: [Dorset CCG - Traffic light scheme](#)